Challenges in designing a national surveillance program for inflammatory bowel disease in the United States

Inflammatory Bowel Diseases

Volumn 20, Issue 2, 2014, Pages 398-415

  Long, Millie D ^a   Hutfless, Susan ^b   Kappelman, Michael D ^a   Khalili, Hamed ^c   Kaplan, Gilaad G ^d   Bernstein, Charles N ^e   Frederic Colombel, Jean ^f   Gower Rousseau, Corinne ^g   Herrinton, Lisa ^h   Velayos, Fernando ⁱ   Loftus Jr , Edward V ^j   Nguyen, Geoffrey C ^k   Ananthakrishnan, Ashwin N ^c   Sonnenberg, Amnon ^l   Chan, Andrew ^c   Sandler, Robert S ^a   Atreja, Ashish ^f   Shah, Samir A ^l   Rothman, Kenneth J ^n,o   Leleiko, Neal S ^m   Bright, Renee ^f   Boffetta, Paolo ^f   Myers, Kelly D ^p   Sands, Bruce E ^f   more..

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g UNIV LILLE   (France)

^h KAISER PERMANENTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF TORONTO   (Canada)

^l PORTLAND VA MEDICAL CENTER   (United States)

^m BROWN UNIVERSITY   (United States)

ⁿ RTI HEALTH SOLUTIONS   (United States)

^o BOSTON UNIVERSITY   (United States)

^p QForma Inc   (Mexico)

more..

Author keywords

Clinical areas; Epidemiology; Outcomes research measurements

Indexed keywords

CANADA; COHORT ANALYSIS; CONSENSUS; DISEASE SEVERITY; DISEASE SURVEILLANCE; ELECTRONIC MEDICAL RECORD; FRANCE; FUNDING; GOVERNMENT; HEALTH CARE SYSTEM; HEALTH MAINTENANCE ORGANIZATION; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; ICD-9; INCIDENCE; INFLAMMATORY BOWEL DISEASE; MEDICAID; MEDICAL INFORMATICS; MEDICARE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; TERTIARY CARE CENTER; UNITED STATES; INFLAMMATORY BOWEL DISEASES; MORBIDITY; PROCEDURES; TRENDS;

GOVERNMENT PROGRAMS; HUMANS; INFLAMMATORY BOWEL DISEASES; MORBIDITY; POPULATION SURVEILLANCE; UNITED STATES;

EID: 84893760695     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000435441.30107.8b     Document Type: Review

References (110)

1. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
2. Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17:1603-1609.
3. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424-1429.
4. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13:254-261.
5. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.e42; quiz e30.
6. Ng SC, Bernstein CN, Vatn MH, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013; 62:630-649.
7. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423-439.
8. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
9. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut. 2008;57:1185-1191.
10. Calkins BM, Lilienfeld AM, Garland CF, et al. Trends in incidence rates of ulcerative colitis and Crohn's disease. Dig Dis Sci. 1984;29: 913-920.
11. Sonnenberg A, Wasserman IH. Epidemiology of inflammatory bowel disease among U.S. military veterans. Gastroenterology. 1991;101:122-130.
12. Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology. 1991;100:143-149.
13. Kurata JH, Kantor-Fish S, Frankl H, et al. Crohn's disease among ethnic groups in a large health maintenance organization. Gastroenterology. 1992;102:1940-1948.
14. Sonnenberg A. Demographic characteristics of hospitalized IBD patients. Dig Dis Sci. 2009;54:2449-2455.
15. Sewell JL, Yee HF Jr, Inadomi JM. Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2010;16:204-207.
16. Carr I, Mayberry JF. The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first- and secondgeneration South Asians in Leicester (1991-1994). Am J Gastroenterol. 1999;94:2918-2922.
17. Malaty HM, Fan X, Opekun AR, et al. Rising incidence of inflammatory bowel disease among children: a 12-year study. J Pediatr Gastroenterol Nutr. 2010;50:27-31.
18. Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, et al. Incidence, clinical characteristics, and natural history of pediatric IBD in wisconsin: a population-based epidemiological Study. Inflamm Bowel Dis. 2013; 19:1218-1223.
19. Abramson O, Durant M, Mow W, et al. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. J Pediatr. 2010;157:233-239.e1.
20. Herrinton LJ, Liu L, Lewis JD, et al. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol. 2008;103:1998-2006.
21. Weng X, Liu L, Barcellos LF, et al. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern California-managed care organization. Am J Gastroenterol. 2007;102: 1429-1435.
22. Herrinton LJ, Liu L, Lafata JE, et al. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis. 2007;13:451-461.
23. Hutfless SM, Weng X, Liu L, et al. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology. 2007;133:1779-1786.
24. Sands BE, LeLeiko N, Shah SA, et al. OSCCAR: Ocean State Crohn's and Colitis Area Registry. Med Health R I. 2009;92:82-85
25. Askling J, Dickman PW, Karlen P, et al. Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet. 2001;357:262-266.
26. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228- 1233.
27. Soderlund S, Granath F, Brostrom O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010;138:1697-1703.
28. Ma C, Crespin M, Proulx MC, et al. Postoperative complications following colectomy for ulcerative colitis: a validation study. BMC Gastroenterol. 2012;12:39.
29. Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012;107:1879-1887.
30. de Silva S, Ma C, Proulx MC, et al. Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:972-980.
31. Soon IS, Wrobel I, deBruyn JC, et al. Postoperative complications following colectomy for ulcerative colitis in children. J Pediatr Gastroenterol Nutr. 2012;54:763-768.
32. Rezaie A, Quan H, Fedorak RN, et al. Development and validation of an administrative case definition for inflammatory bowel diseases. Can J Gastroenterol. 2012;26:711-717.
33. Kaplan GG, Hubbard J, Panaccione R, et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg. 2011;146:959-964.
34. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol. 2006;101:1559-1568.
35. Bernstein CN, Rawsthorne P, Cheang M, et al. A population-based case control study of potential risk factors for IBD. Am J Gastroenterol. 2006; 101:993-1002.
36. Bernstein CN, Singh S, Graff LA, et al. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol. 2010;105:1994-2002.
37. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011;106:731-736.
38. Graff LA, Vincent N, Walker JR, et al. A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1882-1889.
39. Rawsthorne P, Clara I, Graff LA, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products. Gut. 2012;61:521-527.
40. Singh H, Nugent Z, Demers AA, et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011;141:1612-1620.
41. Singh H, Nugent Z, Demers AA, et al. Screening for cervical and breast cancer among women with inflammatory bowel disease: a populationbased study. Inflamm Bowel Dis. 2011;17:1741-1750.
42. Targownik LE, Leslie WD, Carr R, et al. Longitudinal change in bone mineral density in a population-based cohort of patients with inflammatory bowel disease. Calcif Tissue Int. 2012;91:356-363.
43. Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228-1235.
44. Boualit M, Salleron J, Turck D, et al. Long-term outcome after first intestinal resection in pediatric-onset crohn's disease: a population-based study. Inflamm Bowel Dis. 2013;19:7-14.
45. Charpentier C, Salleron J, Savoye G, et al. Natural history of elderlyonset inflammatory bowel disease: a population-based cohort study. Gut. 2013.
46. Chouraki V, Savoye G, Dauchet L, et al. The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Aliment Pharmacol Ther. 2011;33:1133-1142.
47. Crombe V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis. 2011;17:2144-2152.
48. Gower-Rousseau C, Vasseur F, Fumery M, et al. Epidemiology of inflammatory bowel diseases: new insights from a French populationbased registry (EPIMAD). Dig Liver Dis. 2013;45:89-94.
49. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845-857.
50. Savoye G, Salleron J, Gower-Rousseau C, et al. Clinical predictors at diagnosis of disabling pediatric Crohn's disease. Inflamm Bowel Dis. 2012;18:2072-2078.
51. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135:1106-1113.
52. Liu L, Allison JE, Herrinton LJ. Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in a northern California managed care organization. Pharmacoepidemiol Drug Saf. 2009;18:1086-1093.
53. Available at: http://www.cms.gov/Research-Statistics-Data-and-Systems/ Research/ResearchGenInfo/CMSStatistics.html. Accessed August 1, 2013.
54. Shaukat A, Virnig DJ, Salfiti NI, et al. Is inflammatory bowel disease an important risk factor among older persons with colorectal cancer in the United States? A population-based case-control study. Dig Dis Sci. 2011; 56:2378-2383.
55. Shaukat A, Virnig DJ, Howard D, et al. Crohn's disease and small bowel adenocarcinoma: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2011;20:1120-1123.
56. Sanoff HK, Carpenter WR, Sturmer T, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012;30:2624-2634.
57. Braithwaite D, Zhu W, Hubbard RA, et al. Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? J Natl Cancer Inst. 2013;105:334-341.
58. Baxter NN, Warren JL, Barrett MJ, et al. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol. 2012;30: 2664-2669.
59. Haynes K, Beukelman T, Curtis JR, et al. Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum. 2013;65:48-58.
60. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factoralpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306:2331-2339.
61. Arora G, Singh G, Vadhavkar S, et al. Incidence and risk of intestinal and extra-intestinal complications in Medicaid patients with inflammatory bowel disease: a 5-year population-based study. Dig Dis Sci. 2010; 55:1689-1695.
62. Herrinton LJ, Curtis JR, Chen L, et al. Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf. 2011;20:1199-1209.
63. Herrinton LJ, Liu L, Fireman B, et al. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology. 2009;137:502-511.
64. Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146-2153.
65. Velayos FS, Liu L, Lewis JD, et al. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology. 2010;139:1511-1518.
66. St Sauver JL, Grossardt BR, Yawn BP, et al. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. Am J Epidemiol. 2011;173:1059-1068.
67. St Sauver JL, Grossardt BR, Yawn BP, et al. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol. 2012;41:1614-1624.
68. St Sauver JL, Grossardt BR, Leibson CL, et al. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clin Proc. 2012;87: 151-160.
69. Rocca WA, Yawn BP, St Sauver JL, et al. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc. 2012;87:1202-1213.
70. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161-1168.
71. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000;46:336-343.
72. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a populationbased cohort. Gastroenterology. 1999;117:49-57.
73. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology. 2006;130:1039-1046.
74. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875-880.
75. Loftus EV Jr, Crowson CS, Sandborn WJ, et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002;123:468-475.
76. Loftus EV Jr, Achenbach SJ, Sandborn WJ, et al. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003;1:465-473.
77. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a populationbased study. Gastroenterology. 2001;121:255-260.
78. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a populationbased cohort. Gastroenterology. 2010;139:1147-1155.
79. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 2012;107:1693-1701.
80. Jess T, Loftus EV Jr, Harmsen WS, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006;55:1248-1254.
81. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol. 2003;98:1064-1072.
82. Ananthakrishnan AN, Higuchi LM, Huang ES, et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med. 2012;156:350-359.
83. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology. 2012;142:482-489.
84. Ananthakrishnan AN, Khalili H, Pan A, et al. Association between depressive symptoms and incidence of Crohn's disease and ulcerative colitis: results from the Nurses' Health Study. Clin Gastroenterol Hepatol. 2013;11:57-62.
85. Khalili H, Ananthakrishnan AN, Higuchi LM, et al. Early life factors and risk of inflammatory bowel disease in adulthood. Inflamm Bowel Dis. 2013;19:542-547.
86. Khalili H, Higuchi LM, Ananthakrishnan AN, et al. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut. 2013; 62:1153-1159.
87. Thirumurthi S, Chowdhury R, Richardson P, et al. Validation of ICD-9- CM diagnostic codes for inflammatory bowel disease among veterans. Dig Dis Sci. 2010;55:2592-2598.
88. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol. 1996;91:44-48.
89. Delco F, Sonnenberg A. Military history of patients with inflammatory bowel disease: an epidemiological study among U.S. veterans. Am J Gastroenterol. 1998;93:1457-1462.
90. Hou JK, Chang M, Nguyen T, et al. Automated identification of surveillance colonoscopy in inflammatory bowel disease using natural language processing. Dig Dis Sci. 2013;58:936-941.
91. Hou JK, Kramer JR, Richardson P, et al. Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit. Aliment Pharmacol Ther. 2012;36: 1049-1056.
92. Khan N, Abbas AM, Bazzano LA, et al. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther. 2012;36:755-764.
93. Khan N, Abbas AM, Moehlen M, et al. Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the veterans affairs health care system. Inflamm Bowel Dis. 2013;19:1379-1383.
94. Sonnenberg A, Richardson PA, Abraham NS. Hospitalizations for inflammatory bowel disease among US military veterans 1975-2006. Dig Dis Sci. 2009;54:1740-1745.
95. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines-a nationwide retrospective cohort study. Gastroenterology. 2013;145:1007-1015.
96. Khan N, Abbas AM, Almukhtar RM, et al. Prevalence and predictors of low bone mineral density in males with ulcerative colitis. J Clin Endocrinol Metab. 2013;98:2368-2375.
97. Khan N, Abbas A, Williamson A, et al. Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. Dig Dis Sci. 2013;58:2963-2969.
98. Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNFalpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99-105.
99. Chiorean MV, Pokhrel B, Adabala J, et al. Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. Dig Dis Sci. 2011;56:1489-1495.
100. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
101. Sultan K, Korelitz BI, Present D, et al. Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:1855-1858.
102. Gearhart SL, Nathan H, Pawlik TM, et al. Outcomes from IBD-associated and non-IBD-associated colorectal cancer: a Surveillance Epidemiology and End Results Medicare study. Dis Colon Rectum. 2012; 55:270-277.
103. Shaukat A, Salfiti NI, Virnig DJ, et al. Is ulcerative colitis associated with survival among older persons with colorectal cancer in the US? A population-based case-control study. Dig Dis Sci. 2012;57: 1647-1651.
104. Wang YR, Cangemi JR, Loftus EV Jr, et al. Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. Am J Gastroenterol. 2013; 108:444-449.
105. Long MD, Kappelman MD, Martin CF, et al. Development of an internetbased cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis. 2012; 18:2099-2106.
106. Cohen AB, Lee D, Long MD, et al. Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Dig Dis Sci. 2013;58:1322-1328.
107. Ananthakrishnan AN, Long MD, Martin CF, et al. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. Clin Gastroenterol Hepatol. 2013;11:965-971.
108. Atreja A, Achkar JP, Jain AK, et al. Using technology to promote gastrointestinal outcomes research: a case for electronic health records. Am J Gastroenterol. 2008;103:2171-2178.
109. Reddy SI, Friedman S, Telford JJ, et al. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol. 2005;100: 1357-1361.
110. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.